Lantheus Holdings (LNTH) Other Accumulated Expenses (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Other Accumulated Expenses came in at $23.4 million in Q1 2026, up 79.11% year-on-year from $13.0 million in Q1 2025, and up 59.11% on a QoQ basis from $14.7 million in Q4 2025.
Lantheus Holdings (LNTH) Other Accumulated Expenses (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Other Accumulated Expenses data on file, last reported at $23.4 million in Q1 2026.
- On a quarterly basis, Other Accumulated Expenses rose 79.11% year-over-year to $23.4 million in Q1 2026; TTM through Mar 2026 was $23.4 million, a 79.11% increase from a year earlier, with the FY2025 full-year figure at $14.7 million, up 41.28% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $23.4 million, up from $14.7 million in the prior quarter.
- Over the last five years, Other Accumulated Expenses for LNTH reached as high as $54.7 million in Q1 2024 and fell as low as $7.5 million in Q1 2022.
- Historically, Other Accumulated Expenses has averaged $19.4 million across 5 years, with a median of $14.7 million in 2025.
- Across the five-year window, Other Accumulated Expenses soared 572.0% in 2023 and tumbled 76.14% in 2025, its largest moves.
- Year by year, Other Accumulated Expenses stood at $25.5 million in 2022, then slumped by 53.36% to $11.9 million in 2023, then decreased by 12.67% to $10.4 million in 2024, then soared by 41.28% to $14.7 million in 2025, then soared by 59.11% to $23.4 million in 2026.
- Per Business Quant data, the three most recent Other Accumulated Expenses figures were $23.4 million in Q1 2026, $14.7 million in Q4 2025, and $20.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.37 Mn |
| Dec 31, 2025 | 14.69 Mn |
| Sep 30, 2025 | 20.93 Mn |
| Jun 30, 2025 | 9.80 Mn |
| Mar 31, 2025 | 13.05 Mn |
| Dec 31, 2024 | 10.40 Mn |
| Sep 30, 2024 | 14.83 Mn |
| Jun 30, 2024 | 16.80 Mn |
| Mar 31, 2024 | 54.69 Mn |
| Dec 31, 2023 | 11.91 Mn |
| Sep 30, 2023 | 22.56 Mn |
| Jun 30, 2023 | 11.16 Mn |
| Mar 31, 2023 | 50.38 Mn |
| Dec 31, 2022 | 25.53 Mn |
| Sep 30, 2022 | 11.14 Mn |
| Jun 30, 2022 | 11.01 Mn |
| Mar 31, 2022 | 7.50 Mn |
| Dec 31, 2021 | 5.35 Mn |
| Dec 31, 2020 | 6.13 Mn |
| Dec 31, 2019 | 2.10 Mn |